Pomalidomide in heavily pretreated refractory multiple myeloma: a case report

Multiple Myeloma (MM)

Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma

Future Oncol.

Conticello C, Parisi M, Romano A, Calafiore V, Ancora F, La Fauci A1, Consoli ML, Di Raimondo F

doi: 10.2217/fon-2016-0368

COMMENTED

Skin CancerMultiple Myeloma (MM)

Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation

Hematol Oncol.

Mey UJ, Renner C, von Moos R

doi: 10.1002/hon.2353.

Multiple Myeloma (MM)

A phase 1B study of venetoclax combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Multiple Myeloma (MM)

Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison

Am J Hematol.

Usmani SZ, Diels J, Ito T, Mehra M, Khan I, Lam A

doi: 10.1002/ajh.24781.

Multiple Myeloma (MM)

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes

Leukemia.

Hari P, Mateos MV, Abonour R, Knop S, Bensinger W, Ludwig H, Song K, Hajek R, Moreau P, Siegel DS, Feng S, Obreja M, Aggarwal SK, Iskander K, Goldschmidt H

doi: 10.1038/leu.2017.122.

Lymphoma

CD19-Directed CAR T Cells Treatment in a Patient With Refractory DLBCL and CNS Involvement

healthbook TIMS Oncology Hematology

Ring A, Müller A

doi: 10.36000/hbT.OH.2019.01.005

Leukemia

Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy

J Clin Pharm Ther.

Lun Y, Yang JJ, Wu Y

doi: 10.1111/jcpt.12577.

Lymphoma

Hodgkin’s Lymphoma after Autologous Stem-Cell Transplantation: Effective Consolidation with Brentuximab Vedotin

healthbook Times Oncology Hematology

Schmidt A

doi: 10.36000/hbT.OH.2020.06.025

Sarcoma

Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion

Ann Oncol.

Bielack SS, Cox MC, Nathrath M, Apel K, Blattmann C, Holl T, Jenewein R, Klenk U, Klothaki P, Müller-Abt P, Ortega-Lawerenz S, Reynolds M, Scheer M, Simon-Klingenstein K, Stegmaier S, Tupper R, Vokuhl C, von Kalle T

doi: 10.1093/annonc/mdz382.Visit the original publication at ncbi.nlm.nih.gov

Related content

Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma

Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation

A phase 1B study of venetoclax combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes

CD19-Directed CAR T Cells Treatment in a Patient With Refractory DLBCL and CNS Involvement

Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy

Hodgkin’s Lymphoma after Autologous Stem-Cell Transplantation: Effective Consolidation with Brentuximab Vedotin

Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion